Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 12Parkinson Disease 4, Autosomal Dominant Lewy Body 8Melanoma 6Carcinoma, Renal Cell 6Neoplasms 5Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Liver Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Metastatic Castration-Resistant Prostate Cancer 1

Interventions

pembrolizumab 2lenvatinib 1abemaciclib 1Tablets 1Docetaxel 1Combined Modality Therapy 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Adenoid Cystic × lenvatinib × Clear all
NCT05774899 2025-06-17

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
32 enrolled

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡